NHS England is providing targeted funding to STPs for multi-agency suicide prevention plans. The South East region suicide prevention lead is working to raise awareness regarding ‘shamanic hallucinogenic drugs’ and NHSE/I will share any learning generated by the South East regional team nationally. (AI summary)
View full response
package with the National Confidential Inquiry into Suicide and Safety in Mental Health (NCISH) and National Collaborating Centre for Mental Health (NCCMH) working together to support STPs in their quality improvement plans, as part of the national suicide prevention programme. Key components of this support programme include supporting services with safety planning, using resources such as The National Confidential Inquiry into Suicide and Safety in Mental Health (NCISH) ‘Safer services: A toolkit for specialist mental health services and primary care’, which includes guidance for mental health services to work jointly with local substance misuse services and having specific training in place for staff on substance misuse assessment. I know that the South East region suicide prevention lead is working to raise awareness and escalate concerns regarding ‘shamanic hallucinogenic drugs’ via relevant forums to increase awareness and understanding of this risk factor. Furthermore, based on the insights provided in this report, the NHSE/I National team will share any outputs and learning generated by the South East regional team with all other suicide prevention regional leads and teams nationally. In addition to this, as part of the NHS Long Term Plan’s commitment to transform community mental health services, we are investing £181M in psychological therapies for severe mental illness (SMI). This includes the roll-out of ‘understanding psychosis and bipolar disorder’ training, which will be rolled out across staff working in community mental health teams over the next three years. The aim of this training is to ensure those working with people presenting with psychosis recognise the diverse bio-psychosocial factors (including substance use) that can impact upon a person's mental health. Your concerns around the lack of awareness of Shamanic hallucinogens are noted. It would be relevant that colleagues at Public Health England are better placed to consider this in their work on “Misuse of illicit drugs and medicines guidance”. I have shared your report and our response with my colleague Yvonne Doyle. Thank you for bringing these important patient safety issues to my attention and please do not hesitate to contact me should you need any further information.